Volume | 1,903 |
|
|||||
News | - | ||||||
Day High | 25.07 | Low High |
|||||
Day Low | 25.03 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
SWK Holdings Corporation | SWKHL | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
25.07 | 25.03 | 25.07 | 25.08 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
13 | 1,903 | US$ 25.05 | US$ 47,665 | - | 24.475 - 25.88 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
11:24:15 | 400 | US$ 25.03 | USD |
SWK Holdings Corporation Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
313.2M | 12.50M | - | 44.06M | 15.89M | 1.27 | 19.72 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
SWK News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SWKHL Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 25.01 | 25.15 | 24.95 | 25.04 | 2,541 | 0.02 | 0.08% |
1 Month | 25.15 | 25.21 | 24.95 | 25.03 | 4,284 | -0.12 | -0.48% |
3 Months | 25.00 | 25.88 | 24.81 | 25.08 | 3,462 | 0.03 | 0.12% |
6 Months | 24.85 | 25.88 | 24.745 | 25.03 | 4,624 | 0.18 | 0.72% |
1 Year | 24.60 | 25.88 | 24.475 | 24.96 | 5,051 | 0.43 | 1.75% |
3 Years | 24.60 | 25.88 | 24.475 | 24.96 | 5,051 | 0.43 | 1.75% |
5 Years | 24.60 | 25.88 | 24.475 | 24.96 | 5,051 | 0.43 | 1.75% |
SWK Description
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment. |